Treat the Cause of Heart Failure Progression.

Revivent™ Myocardial Anchoring System and Revivent TC™ TransCatheter Ventricular Enhancement System.

In response to the urgent need for new therapies that restore ventricular geometry and function, BioVentrix developed the Revivent System§ and the Revivent TC System*, both which facilitate Less Invasive Ventricular Enhancement™ (LIVE™). The Revivent Systems are simple, off-pump treatment options that are safer and less invasive than conventional surgical ventricular restoration. The LIVE procedure is beneficial because it:

  • May not require cardiopulmonary bypass
  • Does not require cutting into the LV wall (ventriculotomy), as with standard surgical treatment, thereby eliminating the risks of ventriculotomy suture-line bleeding and introduction of air into the heart
  • May result in reduction of LV volume, primarily as a result of decrease in LV circumference, which conveys lower wall tension (a recognized cause of progression of heart failure)
  • Eliminates substantial risks present in standard surgical ventricular reconstruction (SVR)
  • Is a less complex treatment than SVR
  • Allows for "minimal-access surgery"
  • Offers potentially better clinical outcomes and quality of life

Revivent System placement overview.

How prevalent is scar in heart failure patients?

Despite advances in percutaneous coronary intervention (PCI), approximately 35% of patients with acute coronary syndrome develop scar formation in the left ventricular for several reasons.1 To impact survival, PCI must be performed within the first 12 hours; however, 20% of patients seek intervention outside of this treatment window.2 As well, not all patients that receive PCI avoid scar formation; nearly 20% of PCI patients still develop scar that involves greater than a third of their LV mass.3

For thousands of patients across the European Union, scarred myocardium begins the adverse remodeling cycle of left ventricular dilatation. This increase in circumference and volume results in excessive wall tension, which triggers the progression of heart failure. For these patients, the Revivent Systems can provide an immediate reversal of the progression of the debilitating symptoms associated with heart failure.

The Revivent TC™ TransCatheter Ventricular Enhancement System requires regulatory approval and is not yet commercially available.

Mandelzweig et al. The Second Euro Heart Survey on Acute Coronary Syndromes: Characteristics, Treatment, and Outcome of Patients with ACS in Europe and the Mediterranean Basin in 2004, Eur Heart J. 2006;27:2285-2293.

Gibbons R et al. Acute PCI for ST-Segment Elevation Myocardial Infarction Is Later Better Than Never? JAMA. 2005;293(23):2930-31.

Stone G et al. Predictors of Infarct Size After Primary Coronary Angioplasty in Acute Myocardial Infarction from Pooled Analysis from Four Contemporary Trials. Am J of Cardiol.
2007;100(9):1370-75.